When you diet, it is actually better and more effective to eat

“Patients with asthma ABPA have an urgent need for new therapeutic options that reduce the severe side effects associated with current standard of care treatments,” saidTed Raad, chief executive officer of Pulmatrix. “We view this FDA Fast Track designation as continued support that Pulmazole, enabled by Pulmatrix’s iSPERSE delivery technology, has the potential to advance towards a first line treatment option for ABPA patients. With our Phase 1/1b trial successfully meeting all endpoints, we are now focused on advancing our ongoing Phase 2 study, leveraging the important advantages of Fast Track designation, and look forward to reporting study results by year end.”.